Screening, analysis and in vitro vasodilatation of effective components from Ligusticum Chuanxiong.
Effective components, ligustilide and butylidenephthalide, from Ligusticum Chuanxiong (Ligusticum wallichii Franchat, Umbelliferae) were screened and identified by using a cell membrane chromatography (CMC) and a gas chromatography/mass spectrometry (GC/MS). The components showed the effects of inhibiting vasoconstriction in vitro on rat abdominal aorta segments. The screening procedure was performed in a rat artery CMC column (50 mm x 2.0 mm I.D.) with a sodium phosphate buffer (pH 7.4) as mobile phase at 37 degrees C. The identification was accomplished by a DB-5MS 30 m capillary column (0.25 mm I.D., 0.25 microm film thickness) with helium as carrier gas operating under program control temperature and electron impact ionization mass spectrometer in a scan mode. Results demonstrated that ligustilide and butylidenephthalide can act on rat artery cell membrane similar to verapamil in CMC system. They significantly inhibited the vasoconstrictions induced by norepinephrine bitartrate (NE) and calcium chloride (CaCl2). The relaxing effect of ligustilide on the NE- and CaCl2-induced constrictions is more potent than that of butylidenephthalide. Ligustilide and butylidenephthalide seem to be the two main effective components of Ligusticum Chuanxiong as a traditional Chinese medicine for treating blood vessel diseases.
Liang
Ming-Jin
MJ
Department of Pharmacy, School of Medicine, Xi'an Jiaotong University, No. 76, Yanta Weststreet, #120, Xi'an, Shaanxi Province 710061, PR China.
He
Lang-Chong
LC
Yang
Guang-De
GD
D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects; D002122:Calcium Chloride / Q000494:pharmacology; D008401:Gas Chromatography-Mass Spectrometry; D066298:In Vitro Techniques; D030004:Ligusticum / Q000737:chemistry*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010796:Phthalic Anhydrides / Q000494:pharmacology; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D010938:Plant Oils / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*
D010276:Parasympatholytics; D010796:Phthalic Anhydrides; D010936:Plant Extracts; D010938:Plant Oils; C027820:ligustilide; D002122:Calcium Chloride; D015107:4-Butyrolactone; C026105:butylidenephthalide; D009638:Norepinephrine